AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01134328
Drug: AC-150 Combo
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye for up to 14 days
Trial: NCT01134328
Drug: AC-150A 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye once per day for up to 14 days
Trial: NCT01497665
Drug: GRN1005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg/m2 IV every 3 weeks
Trial: NCT01692184
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03066115
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description.
Trial: NCT03066115
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description.
Trial: NCT00380939
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01101217
Drug: Zinc Supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
Trial: NCT01101217
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily for 6 weeks
Trial: NCT00976495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 12 weeks
Trial: NCT02418572
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)
Trial: NCT02418572
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG
Trial: NCT04405921
Drug: Azithromycin 250 MG
RxNorm normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally or via gastric tube
Trial: NCT00092300
Drug: MK0966, rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092300
Drug: Comparator: valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04073953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Trial: NCT02256254
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 Simvastatin capsules of 20 mg every evening for 14 days
Trial: NCT02256254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules every evening for 14 days
Trial: NCT01122641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched tablets
Trial: NCT00738023
Drug: Normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
Trial: NCT04678193
Drug: Coromec Registry with ECL-19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
Trial: NCT01226602
Drug: AZD6140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2Y12 receptor antagonist
Trial: NCT01226602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03024151
Drug: Comthyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T4/T3 combination replacement
Trial: NCT02132169
Drug: Drug: AC-170 0.24%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00686699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT00736385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2000 mg daily for 12 months
Trial: NCT03276494
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous administration of hypertonic saline
Trial: NCT02411994
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04065295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT01231802
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
Trial: NCT03020797
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03760562
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucocorticoids.
Trial: NCT01231802
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
Trial: NCT02283242
Drug: Placebo (for galantamine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use for 12 weeks
Trial: NCT00886756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01064518
Drug: Placebo (Dose B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
Trial: NCT03601091
Drug: Precedex 200 MCG in 2 ML Injection
RxNorm normalized name: Precedex 200 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy of the drug
Trial: NCT03988842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution reconstituted to mimic Alteplase 50mg vial
Trial: NCT01837927
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 52 weeks
Trial: NCT01227265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant-matching placebo oral tablet taken twice daily
Trial: NCT04005287
Drug: Placebo Low Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Solution
Trial: NCT04005287
Drug: Placebo High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Solution
Trial: NCT02737007
Drug: [14C]-GSK3191607
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
Trial: NCT00003605
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04915846
Drug: ApoTamox 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
Trial: NCT04915846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT01404169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
Trial: NCT00047528
Drug: Alcon Investigational Agent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03776500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo supplied as powder for oral solution
Trial: NCT02960204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00074165
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
Trial: NCT02044809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03225833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride
Trial: NCT01566006
Drug: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
Trial: NCT01981031
Drug: BioChaperone® Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
Trial: NCT01981031
Drug: Humalog® Mix25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
Trial: NCT02439866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatinous capsules filled with sugar as placebo
Trial: NCT02439866
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
Trial: NCT00409071
Drug: Cocculine®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
Trial: NCT00409071
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
Trial: NCT06119126
Drug: SDF1
RxNorm normalized name: Stromal cell-derived factor 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical SDF application
Trial: NCT00768612
Drug: SCA-136 50mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00768612
Drug: SCA-136 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00768612
Drug: SCA-136 300mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03676413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily inhalation throughout the study
Trial: NCT03485404
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: folic acid tablets, 5mg/tablet, 1 tablet/day
Trial: NCT03822520
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400mg capsule
Trial: NCT03812874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)
Trial: NCT05568017
Drug: peptide receptor radionuclide therapy with Y-90-DOTATOC
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
Trial: NCT00788463
Drug: Intranasal Beclomethasone aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
Trial: NCT06044467
Drug: Placebo - Study Part One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT06044467
Drug: Placebo - Study Part Two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT01296646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive pill to control for non-pharmacological responses.
Trial: NCT04080336
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
Trial: NCT04080336
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
Trial: NCT03484416
Drug: Calcium Carbonate 1500 Mg with Vitamin D
RxNorm normalized name: Calcium Carbonate 1500 mg with Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
Trial: NCT00332241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, once daily, 8 weeks
Trial: NCT00730249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily according to an individual titration schedule
Trial: NCT02487069
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX is used in all the patients for GVHD prophylaxis.
Trial: NCT01651481
Drug: HCP1102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01651481
Drug: Singulair and Xyzal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02179008
Drug: DE-117 Low/Middle Dose ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low/Middle Dose DE-117
Trial: NCT02179008
Drug: DE-117 Middle/High Dose ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle/High Dose DE-117
Trial: NCT02243306
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
Trial: NCT03298802
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
Trial: NCT00171379
Drug: Enteric-Coated Mycophenolate Sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02868801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same intervention as the experimental group
Trial: NCT02477800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01586286
Drug: Placebo Ointment Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Trial: NCT02108795
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
Trial: NCT02108795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01182636
Drug: Differin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Topical Gel
Trial: NCT01182636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel Base
Trial: NCT03202667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Placebo oral tablet once daily for 28 days
Trial: NCT03946592
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject the Drug into submental fat via subcutaneous
Trial: NCT03946592
Drug: DWJ211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject the Drug into submental fat via subcutaneous
Trial: NCT01808911
Drug: Steroid + cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006786
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006786
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02622568
Drug: Veregen only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Veregen 15% ointment on affected areas twice daily
Trial: NCT02558725
Drug: two capsules of aktiferrin F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two capsules of Aktiferrin F or Foliferrin
Trial: NCT00002893
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002893
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00872872
Drug: AZT/3TC 2 weeks after delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
Trial: NCT00579527
Drug: Methylprednisolone or Prednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
Trial: NCT04445935
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive standard anticoagulation with LMWH/UFH
Trial: NCT03631433
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: identical appearing tablets containing 600 mg of ibuprofen
Trial: NCT03631433
Drug: ibuprofen 600 mg and acetaminophen 650 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: identical appearing tablets of the combination of ibuprofen and acetaminophen
Trial: NCT00774397
Drug: BI 201335 NA 240 mg QD / LI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
Trial: NCT00774397
Drug: PegIFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
Trial: NCT00774397
Drug: BI 201335 NA 120mg QD / LI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
Trial: NCT00774397
Drug: PegIFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
Trial: NCT00774397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03614273
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
Trial: NCT05397262
Drug: Chemotherapy 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/m\^2 civ 120h; d 1-5, 29-33
Trial: NCT01195636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of Placebo ointment
Trial: NCT03961529
Drug: 0.3% OPA-15406 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily